Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment Outcomes of Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid

  • Oki Nugraha Putra (Department of Clinical and Community Pharmacy, Study Program of Pharmacy, Faculty of Medicine, Hang Tuah University) ;
  • Telly Purnamasari (Pre-Clinical and Clinical Studies, National Research and Innovation Agency)
  • Received : 2023.11.24
  • Accepted : 2023.12.07
  • Published : 2024.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Choi H, Jeong D, Kang YA, Jeon D, Kang HY, Kim HJ, et al. Impact of anti-tuberculosis drug use on treatment outcomes in patients with pulmonary fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide retrospective cohort study with propensity score matching. Tuberc Respir Dis (Seoul) 2023;86:234-44. 
  2. Bhering M, Duarte R, Kritski A. Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000-2016. PLoS One 2019;14:e0218299. 
  3. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Drug-resistant tuberculosis treatment 2022 update. Geneva: WHO; 2022. 
  4. Saifullah A, Mallhi TH, Khan YH, Iqbal MS, Alotaibi NH, Alzarea AI, et al. Evaluation of risk factors associated with the development of MDR- and XDR-TB in a tertiary care hospital: a retrospective cohort study. PeerJ 2021;9:e10826. 
  5. Kempker RR, Barth AB, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, et al. Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2015;59:3149-55. 
  6. Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, et al. Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic/pharmacodynamic target attainment to guide dose selection. Antimicrob Agents Chemother 2019;63:e00279-19. 
  7. Soedarsono S, Kusmiati T, Wulaningrum PA, Permatasari A, Indrawanto DW. Factors cause of switching shorter regimen to longer regimen in multidrug-resistant/rifampicin-resistant tuberculosis treated patients in Dr. Soetomo Hospital Surabaya, Indonesia. Indian J Forensic Med Toxicol 2021;15:1576-82. 
  8. Lestari BW, Nijman G, Larasmanah A, Soeroto AY, Santoso P, Alisjahbana B, et al. Management of drug-resistant tuberculosis in Indonesia: a four-year cascade of care analysis. Lancet Reg Health Southeast Asia 2023:100294. 
  9. Putra ON, Yulistiani Y, Soedarsono S, Subay S. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: a systematic review. Int J Mycobacteriol 2023;12:1-9. 
  10. Kang H, Jo KW, Jeon D, Yim JJ, Shim TS. Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea. Respir Med 2020;167:105956. 
  11. Hwang H, Kang H, Kwon YS, Jeon D, Shim TS, Yim JJ. Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid. Clin Infect Dis 2021;73:1362-9. 
  12. Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet 2022;400:1522-30.